The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Capability of ChatGPT Reduced in Complex Vitreoretinal Scenarios
Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.
Male Sex, Younger Age Linked to Sickle Cell Retinopathy Progression
Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.
Sozinibercept Combination Therapy Exhibits Durability for nAMD, DME
Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.
Semaglutide May Reduce Rates of Diabetic Retinopathy Outcomes
A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X
Presented at ASRS 2024, late-breaking RHONE-X data shows more than 90% of patients experienced the absence of DME after four years of faricimab.
FDA Accepts sBLA for Susvimo in Treatment of DME, Diabetic Retinopathy
The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.
Dilraj Grewal, MD: Development of MNV in Geographic Atrophy in GATHER Trials
Eyes with GA that developed MNV in the GATHER trials experienced a slower growth rate with avaincaptad pegol than with sham treatment.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy
Patients treated with PDS with ranibizumab refilled every nine months maintained vision improvements and experienced consistent safety over two years.
Study Links Maternal Asthma to Blinding Eye Disease in Premature Infants
New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.
Once-Daily Gildeuretinol Acetate Could Halt Progression of Early Stargardt Disease
New data from the TEASE-3 trial presented at the ASRS meeting shows gildeuretinol acetate may blunt disease progression in early-stage Stargardt disease patients.
Carl C. Awh, MD: Two-Year Outcomes of the Port Delivery System for DME
Over 2 years, the Port Delivery System demonstrated continued efficacy with fixed refill-exchange procedures every 24 weeks in the Phase 3 Pagoda trial.
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort
Interim results from the PRISM population extension cohort found that 4D-150 was well tolerated and reduced the mean annualized anti-VEGF injection rate.
NEPTUNE: Oral Brepocitinib Effective in Non-infectious Uveitis at 24 Weeks
At 24 weeks, the oral therapy was well-tolerated and the safety profile remained in line with previous brepocitinib studies and the pharmacological class.
RHONE-X: 90% of Patients Treated with Faricimab Free from DME at 4 Years
New data from RHONE-X at ASRS suggest over 90% of DME patients treated with faricimab (Vabysmo) were DME-free at 4 years, with nearly 80% on 3-4 month dosing intervals.
Nonsterile Gloves Offer Little Protection Against Post-Injection Endophthalmitis, Study Finds
An ASRS 2024 study found no significant difference in post-injection endophthalmitis rates between using nonsterile gloves and not using gloves for anti-VEGF injections.
RESTORE: MCO-010 Significantly Improves Visual Acuity in Retinitis Pigmentosa
Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD
A single Ixo-vec injection showed up to a 95% reduction in annualized anti-VEGF injections, according to first-time 26-week results from the Phase 2 LUNA study.
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry
Pegcetacoplan for 36 months led to fewer absolute scotomatous points on microperimetry than delayed treatment, suggesting its efficacy in preserving vision.
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD
RGX-314 produced by the NAVXpress platform process showed a similar clinical profile to the adherent cell culture process in this Phase 2 pharmacodynamic study.
ANX007 May Protect Visual Function, Structure in Geographic Atrophy
Phase 2 data from the ARCHER study shows a protective effect of ANX007 on visual acuity and anatomical measures in the central macula in patients with GA.
Dilsher Dhoot, MD: Interim Results on OTX-TKI for NPDR in HELIOS
OTX-TKI remained generally well-tolerated in patients with moderately severe to severe NPDR across 48 weeks of the Phase 1 trial.
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression
Katherine Talcott, MD describes a posthoc analysis of the GATHER trials showing how imaging biomarkers of photoreceptor structure predict GA growth.
Veeral Sheth, MD: Assessing EYP-1901 Supplemental Injection Use in Wet AMD
Veeral Sheth, MD describes an assessment of the need for supplemental injection use after EYP-1901 for wet AMD.
PRISM Interim Analysis Finds 4D-150 Reduces Burden, Treatment Interval with Anti-VEGF Therapy
The PRISM trial's 24-week data show 4D-150 reduced anti-VEGF injection rates by 89% in wet AMD, with 77% of patients injection-free at 24 weeks.
CU06 Shows Potential as Oral Therapy for Diabetic Macular Edema
Phase 2a results demonstrated the efficacy and safety of orally administered CU06-1004 and may warrant further clinical studies in DME.
SGLT2 Inhibitors Outclass GLP-1s, DPP4is in Lowering Retinopathy Risk
SGLT2 inhibitors may provide a favorable impact on the risk of sight-threatening diabetic retinal complications compared with other glucose-lowering therapies.
5 Clinical Trials to Watch at ASRS 2024
We break down 5 top trials to keep an eye on at ASRS 2024, taking place in Stockholm, Sweden from July 17 to 20, 2024.
JAK Inhibitor Updates: Upadacitinib and the Level-Up Trial
Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.
HCPLive Five at ADA 2024
Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.
Diabetes Dialogue: ADA 2024 Diabetes Technology Recap
In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.